stoxline Quote Chart Rank Option Currency Glossary
  
Relmada Therapeutics, Inc. (RLMD)
0.6199  0.101 (19.37%)    05-22 15:28
Open: 0.5
High: 0.6421
Volume: 1,015,404
  
Pre. Close: 0.5193
Low: 0.4925
Market Cap: 21(M)
Technical analysis
2025-05-22 3:20:23 PM
Short term     
Mid term     
Targets 6-month :  0.88 1-year :  1.02
Resists First :  0.75 Second :  0.88
Pivot price 0.43
Supports First :  0.45 Second :  0.26
MAs MA(5) :  0.54 MA(20) :  0.42
MA(100) :  0.35 MA(250) :  1.88
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  81.2 D(3) :  81
RSI RSI(14): 64.4
52-week High :  4.46 Low :  0.23
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RLMD ] has closed above the upper band by 4.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 75.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.66 - 0.66 0.66 - 0.67
Low: 0.48 - 0.49 0.49 - 0.49
Close: 0.51 - 0.52 0.52 - 0.52
Company Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Headline News

Tue, 13 May 2025
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript - Insider Monkey

Tue, 13 May 2025
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... - Yahoo Finance

Tue, 13 May 2025
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights - GuruFocus

Tue, 13 May 2025
Relmada Therapeutics Reports Q1 2025 Financial Results - TipRanks

Thu, 08 May 2025
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - TradingView

Thu, 08 May 2025
Relmada Therapeutics, Inc. Announces Conference Call to Discuss Q1 2025 Financial Results and Business Progress - Nasdaq

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 33 (M)
Shares Float 29 (M)
Held by Insiders 17 (%)
Held by Institutions 39.7 (%)
Shares Short 2,030 (K)
Shares Short P.Month 1,620 (K)
Stock Financials
EPS -2.66
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.17
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -73.2 %
Return on Equity (ttm) -132.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -52 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -0.24
PEG Ratio 0
Price to Book value 0.52
Price to Sales 0
Price to Cash Flow -0.4
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android